Hindawi Publishing Corporation Scientifica Volume 2013, Article ID 371569, 4 pages http://dx.doi.org/10.1155/2013/371569
Research Article Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score Elena Myasoedova,1,2 Bharath Manu Akkara Veetil,1 Eric L. Matteson,1,2 Hilal Maradit Kremers,2 Marian T. McEvoy,3 and Cynthia S. Crowson1,2 1
Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA 3 Department of Dermatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA 2
Correspondence should be addressed to Cynthia S. Crowson; [email protected] Received 18 December 2012; Accepted 7 January 2013 Academic Editors: B. Z. Simkhovich and U. Tursen Copyright © 2013 Elena Myasoedova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To examine the utility of the Framingham risk score (FRS) in estimating cardiovascular risk in psoriasis. Methods. We compared the predicted 10-year risk of cardiovascular events, namely, cardiovascular death, myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting using the FRS, to the observed risk of cardiovascular events in a population-based cohort of patients with psoriasis. Patients with incident or prevalent adult-onset psoriasis aged 30–79 years without prior history of cardiovascular disease were included. Results. Among the 1197 patients with predicted risk scores, the median FRS was 6.0%, while the observed 10-year cardiovascular risk was 6.9% (standardized incidence ratio (SIR): 1.14; 95% confidence interval (CI): 0.92–1.42). The SIR was not elevated for women nor for men. The differences between observed and predicted cardiovascular risks in patients
Research Article Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score Elena Myasoedova,1,2 Bharath Manu Akkara Veetil,1 Eric L. Matteson,1,2 Hilal Maradit Kremers,2 Marian T. McEvoy,3 and Cynthia S. Crowson1,2 1
Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA 3 Department of Dermatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA 2
Correspondence should be addressed to Cynthia S. Crowson; [email protected] Received 18 December 2012; Accepted 7 January 2013 Academic Editors: B. Z. Simkhovich and U. Tursen Copyright © 2013 Elena Myasoedova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To examine the utility of the Framingham risk score (FRS) in estimating cardiovascular risk in psoriasis. Methods. We compared the predicted 10-year risk of cardiovascular events, namely, cardiovascular death, myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting using the FRS, to the observed risk of cardiovascular events in a population-based cohort of patients with psoriasis. Patients with incident or prevalent adult-onset psoriasis aged 30–79 years without prior history of cardiovascular disease were included. Results. Among the 1197 patients with predicted risk scores, the median FRS was 6.0%, while the observed 10-year cardiovascular risk was 6.9% (standardized incidence ratio (SIR): 1.14; 95% confidence interval (CI): 0.92–1.42). The SIR was not elevated for women nor for men. The differences between observed and predicted cardiovascular risks in patients
